IGC Pharma (IGC) Research & Development (2018 - 2025)

IGC Pharma (IGC) has reported Research & Development for 8 consecutive years, with $1.6 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Research & Development rose 73.17% year-over-year to $1.6 million in Q3 2025; TTM through Sep 2025 was $5.3 million, a 47.17% increase from a year earlier, with the FY2026 full-year figure at $1.3 million, down 65.62% from the prior year.
• Research & Development was $1.6 million for Q3 2025 at IGC Pharma, down from $1.8 million in the prior quarter.
• Over five years, Research & Development peaked at $1.8 million in Q2 2025 and troughed at $276000.0 in Q3 2021.
• A 5-year average of $897631.6 and a median of $882000.0 in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 269.16% in 2022 and plunged 56.85% in 2023, its largest moves.
• Over 5 years, Research & Development stood at $377000.0 in 2021, then soared by 113.79% to $806000.0 in 2022, then grew by 12.03% to $903000.0 in 2023, then fell by 5.65% to $852000.0 in 2024, then surged by 86.38% to $1.6 million in 2025.
• The last three Research & Development figures came in at $1.6 million (Q3 2025), $1.8 million (Q2 2025), and $997000.0 (Q1 2025), per Business Quant data.